Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.

Background: Nicotinamide has been reported to protect against liver steatosis and metabolic imbalances in nonalcoholic fatty liver disease (NAFLD) in animal models.

Objectives: The objective was to investigate the efficacy and safety of nicotinamide supplementation in diabetic NAFLD patients.

Design: This is a prospective randomized controlled open label study.